Literature DB >> 9430211

Vascular disruption birth defects and history of prenatal cocaine exposure: a case control study.

R F Hume1, L S Martin, S F Bottoms, S S Hassan, K Banker-Collins, M Tomlinson, M P Johnson, M I Evans.   

Abstract

OBJECTIVE: To test the hypothesis that prenatal cocaine exposure is associated with a 3-fold increased risk for vascular disruption among malformations. STUDY
DESIGN: A retrospective case-control study was based upon >68,000 delivery records at Hutzel Hospital for a 9-year period. Ascertainment was based upon ICD-9 codes for limb defects, abdominal wall defects, and facial clefts. Transverse limb defects and gastroschisis were defined as cases, and nondisruption anomalies served as controls. Statistical analysis for history of maternal cocaine use reported during pregnancy was performed by chi(2) analysis and the odds ratio determined.
RESULTS: A total of 190 cases of limb anomalies, abdominal wall defects, and cleft lips were identified after exclusion criteria. Statistical analysis was performed on the 119 cases informative for maternal cocaine use during pregnancy. Seven of 34 vascular disruption cases had cocaine exposure reported versus 12 of 85 other malformations controls. The odds ratio for cocaine exposure and vascular disruption is 1.58 (95% confidence interval = 0.55-4.47).
CONCLUSION: The putative association of prenatal cocaine exposure and vascular disruption birth defects remains unresolved, but the attributable risk is very likely less than the 3-fold odds ratio previously reported.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430211     DOI: 10.1159/000264488

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  1 in total

1.  A case-control study of maternal periconceptual and pregnancy recreational drug use and fetal malformation using hair analysis.

Authors:  Anna L David; Andrew Holloway; Louise Thomasson; Argyro Syngelaki; Kypros Nicolaides; Roshni R Patel; Brian Sommerlad; Amie Wilson; William Martin; Lyn S Chitty
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.